Literature DB >> 1711565

Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.

D M Lublin1, K E Coyne.   

Abstract

Decay-accelerating factor (DAF) is a glycosyl-phosphatidylinositol (GPI)-anchored membrane protein that protects cells from complement-mediated damage by regulation of the C3 convertase. To investigate the role of the GPI anchor in the function of DAF, the cDNA encoding human DAF was expressed by transfection in Chinese hamster ovary (CHO) cells. Testing of these DAF transfectants in an antibody plus human complement-mediated cytotoxicity assay demonstrated that DAF protects these cells from cytotoxicity, and that the level of protection increases with expression of surface DAF. A cDNA construct encoding a transmembrane version of DAF (DAF-TM) protects CHO transfectants from cytotoxicity with equal efficiency to DAF. This DAF-TM construct used the TM and cytoplasmic domains of membrane cofactor protein (MCP); an alternate TM version of DAF constructed with the TM and cytoplasmic domains of HLA-B44 showed equivalent protection. The protection from cytotoxicity involved a decrease in the deposition of C3 on the cell, consistent with the effect of DAF on the C3 convertase. A second pair of anchor variants, MCP and a GPI-anchored construct, MCP-PI, were also equivalent in their complement protection. The equivalent function of GPI-anchored and TM versions of a protein was not expected based on the hypothesized increased lateral mobility of GPI-anchored proteins, which should confer a functional advantage in contacting ligand, in this case, C3b or C4b, on the cell surface. These data suggest either that GPI-anchored and TM versions of a protein have equal lateral mobility in the membrane, or else that increased lateral mobility is not advantageous to DAF or MCP in carrying out their complement inhibitory roles. Furthermore, DAF and MCP demonstrated approximately equal protection of cells from complement-mediated cytotoxicity, suggesting that DAF and MCP provide overlapping levels of protection to cells against damage mediated by the complement system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711565      PMCID: PMC2118896          DOI: 10.1084/jem.174.1.35

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  42 in total

1.  Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor.

Authors:  D M Lublin; J Krsek-Staples; M K Pangburn; J P Atkinson
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

2.  Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol.

Authors:  I Stefanová; I Hilgert; H Kristofová; R Brown; M G Low; V Horejsí
Journal:  Mol Immunol       Date:  1989-02       Impact factor: 4.407

3.  Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system.

Authors:  A Nicholson-Weller; J P March; C E Rosen; D B Spicer; K F Austen
Journal:  Blood       Date:  1985-05       Impact factor: 22.113

4.  Expression of membrane interleukin 1 by fibroblasts transfected with murine pro-interleukin 1 alpha cDNA.

Authors:  R C Fuhlbrigge; S M Fine; E R Unanue; D D Chaplin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.

Authors:  S Schönermark; E W Rauterberg; M L Shin; S Löke; D Roelcke; G M Hänsch
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

Review 6.  Structural and functional roles of glycosyl-phosphatidylinositol in membranes.

Authors:  M G Low; A R Saltiel
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

7.  Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement.

Authors:  M E Medof; D M Lublin; V M Holers; D J Ayers; R R Getty; J F Leykam; J P Atkinson; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

8.  Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.

Authors:  M E Medof; E I Walter; W L Roberts; R Haas; T L Rosenberry
Journal:  Biochemistry       Date:  1986-11-04       Impact factor: 3.162

9.  Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.

Authors:  M A Davitz; M G Low; V Nussenzweig
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

10.  Decay-accelerating factor is present on cultured human umbilical vein endothelial cells.

Authors:  A S Asch; T Kinoshita; E A Jaffe; V Nussenzweig
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more
  40 in total

1.  The major structural subunits of Dr and F1845 fimbriae are adhesins.

Authors:  Cristina P Van Loy; Evgeni V Sokurenko; Steve L Moseley
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Role of Src kinases in mobilization of glycosylphosphatidylinositol-anchored decay-accelerating factor by Dr fimbria-positive adhering bacteria.

Authors:  Christophe J Queval; Valérie Nicolas; Isabelle Beau
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

3.  Vaccination with purified Dr Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr adhesin.

Authors:  Pawel Goluszko; Elzbieta Goluszko; Bogdan Nowicki; Stella Nowicki; Vsevolod Popov; Hui-Qun Wang
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.

Authors:  T Seya; M Okada; T Hara; M Matsumoto; S Miyagawa; M Oshimura
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

5.  Silencing porcine genes significantly reduces human-anti-pig cytotoxicity profiles: an alternative to direct complement regulation.

Authors:  James R Butler; Gregory R Martens; Jose L Estrada; Luz M Reyes; Joseph M Ladowski; Cesare Galli; Andrea Perota; Conor M Cunningham; Matthew Tector; A Joseph Tector
Journal:  Transgenic Res       Date:  2016-04-21       Impact factor: 2.788

6.  Molecular events contributing to successful pediatric cardiac transplantation in HLA sensitized recipients.

Authors:  Monal Sharma; S A Webber; A Zeevi; T Mohanakumar
Journal:  Hum Immunol       Date:  2019-01-30       Impact factor: 2.850

7.  Glycosyl-phosphatidylinositol-anchored and transmembrane forms of CD46 display similar measles virus receptor properties: virus binding, fusion, and replication; down-regulation by hemagglutinin; and virus uptake and endocytosis for antigen presentation by major histocompatibility complex class II molecules.

Authors:  G Varior-Krishnan; M C Trescol-Biémont; D Naniche; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.

Authors:  Jennifer White; Petra Lukacik; Dirk Esser; Michael Steward; Naomi Giddings; Jeremy R Bright; Sarah J Fritchley; B Paul Morgan; Susan M Lea; Geoffrey P Smith; Richard A G Smith
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

9.  Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection.

Authors:  X Wang; J M Bergelson
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  Epithelial invasion by Escherichia coli bearing Dr fimbriae is controlled by nitric oxide-regulated expression of CD55.

Authors:  Li Fang; Bogdan J Nowicki; Petri Urvil; Pawel Goluszko; Stella Nowicki; Steven L Young; Chandrasekhar Yallampalli
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.